Dr. Reddys Laboratories Ltd.

Dr Reddys Laboratories is currently trading at Rs. 1873.85, up by 39.00 points or 2.13% from its previous closing of Rs. 1834.85 on the BSE.

The scrip opened at Rs. 1835.00 and has touched a high and low of Rs. 1878.30 and Rs. 1835.00 respectively. So far 10322 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1968.60 on 25-Jan-2013 and a 52 week low of Rs. 1528.00 on 19-Jun-2012.

Last one week high and low of the scrip stood at Rs. 1878.30 and Rs. 1732.75 respectively. The current market cap of the company is Rs. 31842.64 crore.

The promoters holding in the company stood at 25.56% while Institutions and Non-Institutions held 40.15% and 17.63% respectively.

Dr Reddy’s Laboratories has launched Zoledronic Acid Injection (5 mg/100 mL), a therapeutic equivalent generic version of Reclast (zoledronic acid) Injection 5 mg/100 mL in the US market on April 03, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr Reddy’s ANDA for Zoledronic Acid Injection (5 mg/100 mL).

Dr Reddy’s Zoledronic Acid Injection (5 mg/100 mL) is available in a single use vial for Intravenous Infusion. According to IMS Health, the Reclast brand had total US sales of approximately $355 million for the most recent twelve months ending February 2013.

Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.